Literature DB >> 18283993

Why do patients die of acute kidney injury?

S Elapavaluru1, J A Kellum.   

Abstract

Acute kidney injury (AKI) is a serious complication in critically-ill patients and portends a high mortality. The incidence of AKI continues to increase and is often underestimated. The intriguing question to both the intensivists and nephrologists is whether the kidney is an innocent bystander in the process of multi-organ systems failure or whether the kidney is initiating various complex metabolic and humoral pathways affecting distant organs contributing to the overall mortality. There is a renewed interest in the last two decades to gain greater insight into various disease pathways and to understand the role of the kidney in multi-organ failure. It is well known that AKI results in significant physiological derangements that underpin remote organ failure. For example, risk of infection and bleeding increase with AKI. Volume overload and acid-base derangements typical of renal dysfunction have serious consequences in the duration and weaning of mechanical ventilation. Recent animal studies suggest that acutely ischaemic kidneys may induce both functional and transcriptional changes in the lung, independent of uraemia. In this review, we have attempted to discuss various physiological derangements and their clinical effects, in the setting of AKI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18283993     DOI: 10.1179/acb.2007.074

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  26 in total

1.  Cytokine production increases and cytokine clearance decreases in mice with bilateral nephrectomy.

Authors:  Ana Andres-Hernando; Belda Dursun; Christopher Altmann; Nilesh Ahuja; Zhibin He; Rhea Bhargava; Charles E Edelstein; Alkesh Jani; Thomas S Hoke; Christina Klein; Sarah Faubel
Journal:  Nephrol Dial Transplant       Date:  2012-07-09       Impact factor: 5.992

Review 2.  Acute kidney injury: what's the prognosis?

Authors:  Raghavan Murugan; John A Kellum
Journal:  Nat Rev Nephrol       Date:  2011-02-22       Impact factor: 28.314

3.  Urine biomarkers predict acute kidney injury in newborns.

Authors:  David J Askenazi; Rajesh Koralkar; Hayden E Hundley; Angela Montesanti; Pushkar Parwar; Srdjan Sonjara; Namasivayam Ambalavanan
Journal:  J Pediatr       Date:  2012-03-16       Impact factor: 4.406

4.  Peptidyl arginine deiminase-4 exacerbates ischemic AKI by finding NEMO.

Authors:  May M Rabadi; Sang Jun Han; Mihwa Kim; Vivette D'Agati; H Thomas Lee
Journal:  Am J Physiol Renal Physiol       Date:  2019-04-03

5.  Urinary kidney injury molecule-1 rapid test predicts acute kidney injury in extremely low-birth-weight neonates.

Authors:  Vesna D Stojanović; Nenad A Barišić; Nada M Vučković; Aleksandra D Doronjski; Amira E Peco Antić
Journal:  Pediatr Res       Date:  2015-06-24       Impact factor: 3.756

6.  Norepinephrine released by intestinal Paneth cells exacerbates ischemic AKI.

Authors:  Sang Jun Han; Mihwa Kim; Vivette Denise D'Agati; H Thomas Lee
Journal:  Am J Physiol Renal Physiol       Date:  2019-12-09

7.  Acute kidney injury is independently associated with mortality in very low birthweight infants: a matched case-control analysis.

Authors:  David J Askenazi; Russell Griffin; Gerald McGwin; Waldemar Carlo; Namasivayam Ambalavanan
Journal:  Pediatr Nephrol       Date:  2009-02-24       Impact factor: 3.714

8.  Cytokines induce small intestine and liver injury after renal ischemia or nephrectomy.

Authors:  Sang Won Park; Sean W C Chen; Mihwa Kim; Kevin M Brown; Jay K Kolls; Vivette D D'Agati; H Thomas Lee
Journal:  Lab Invest       Date:  2010-08-09       Impact factor: 5.662

9.  IL-11 is required for A1 adenosine receptor-mediated protection against ischemic AKI.

Authors:  Joo Yun Kim; Mihwa Kim; Ahrom Ham; Kevin M Brown; Robert W Greene; Vivette D D'Agati; H Thomas Lee
Journal:  J Am Soc Nephrol       Date:  2013-06-27       Impact factor: 10.121

Review 10.  Acute kidney injury in critically ill newborns: what do we know? What do we need to learn?

Authors:  David J Askenazi; Namasivayam Ambalavanan; Stuart L Goldstein
Journal:  Pediatr Nephrol       Date:  2008-12-10       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.